Detection of residual prostate cancer after external radiotherapy. Role of prostate specific antigen and transrectal ultrasonography
โ Scribed by R. Joseph Babaian; Munekado Kojima; Masahito Saitoh; Alberto G. Ayala
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 521 KB
- Volume
- 75
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
In a study population, can digital rectal examination (DRE), transrectal ultrasound (TRUS), and prostate specific antigen (PSA) (monoclonal) effectively detect the majority of clinically relevant cancer? If this is possible, the remaining patients could then be considered for chemopreventive protoco
An understanding of the natural history of changes in prostate-specific antigen (PSA) may be valuable as a surrogate view of prostate dynamics, as a method to differentiate between benign and malignant growth, and as a means to assess the use of PSA as a tool for monitoring activity of chemopreventi
Background. The serum kinetics of prostate-specific antigen (PSA) after radiation therapy for prostate cancer are not well characterized, and the potential prognostic significance of serum half-lives and of serum doubling times is unclear. This study was designed to address those issues. Methods. O